- Ziggma
- Posts
- 🗞️ Pfizer 🤝 Metsera
🗞️ Pfizer 🤝 Metsera
Big Moves Decoded: WDC, ENPH, and more!
In partnership with
Market Performance
S&P 500: 6,832.43 ⬆️ 1.54%
Nasdaq: 23,527.17 ⬆️ 2.27%
Dow Jones: 47,368.63 ⬆️ 0.81%
Pfizer's $10 Billion Bet on Obesity
Pfizer (PFE) is set to acquire Metsera for $86.25 per share, after the biotech's board chose its bid over Novo Nordisk's due to fewer regulatory hurdles.
Pfizer's bid values Metsera at up to $86.25 per share, split between $65.60 in cash and up to $20.65 based on future milestone achievements.
Metsera's board favored the offer not just for its financial appeal, but for its more straightforward path through regulatory hurdles, compared to Novo Nordisk's similar but less certain proposal.
With Novo Nordisk choosing to withdraw rather than increase its bid, shareholder approval now looks likely.
The deal gives Pfizer a crucial entry into the lucrative obesity drug market, even though Metsera's treatments remain years from commercialization.
It marks a setback for Novo as it attempts to catch up to its U.S. rival, Eli Lilly, in the weight-loss space.
Pfizer stock has a Ziggma score of 88 and ranks highly in terms of profitability, valuation, and financial health.
However, the healthcare stock has declined by 9% in the past year, trailing the broader markets.
Our Takeaway
Deal certainty trumped the highest bid in this biotech battle.
Investor reactions—Metsera shares dipping 15% while Pfizer ticked higher—show markets increasingly value regulatory clarity over raw dollars.
As antitrust scrutiny intensifies across pharmaceutical mergers and acquisitions (M&A), expect more boards to prioritize smoother approval paths.
This signals a shift in how biotech deals get done.
Missed OpenAI? The Clock Is Ticking on RAD Intel’s Round
Ground floor opportunity on predictive AI for ROI-based content.
RAD Intel is already trusted by a who’s-who of Fortune 1000 brands and leading global agencies with recurring seven-figure partnerships in place.
$50M+ raised. 10,000+ investors. Valuation up 4,900% in four years*.
Backed by Adobe and insiders from Google. Shares at $0.81 until Nov 20 — then the price moves. Invest now.
This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker “RADI” has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai.
Market Overview 📈
The S&P 500 moved higher on Monday as Senate lawmakers advanced a deal to end the historic U.S. government shutdown, putting investors in a risk-taking mood.
A Senate procedural vote passed with support from eight Democratic senators breaking ranks, advancing a funding bill that would reopen the government into January and reverse recent mass federal layoffs.
The shutdown has driven consumer sentiment to its lowest level in over three years, according to data from the University of Michigan.
Federal agencies have halted key economic reports, including this week's scheduled Consumer Price Index and Producer Price Index.
Flight cancellations continued to mount, with 1,623 U.S. flights grounded on Monday—about 6.3% of the schedule—as air traffic controller shortages persisted.
"It's been a bumpy November for risk assets," said Tim Holland, chief investment officer at Orion, citing shutdown anxiety alongside AI valuation worries.
Microsoft snapped an eight-day losing streak—its longest since 2011—rising 1.9% as tech giants rebounded from concerns over their valuations last week.
The tech-heavy Nasdaq posted its worst week since April's tariff sell-off, losing roughly 3%.
However, with concerns about shutdowns easing, analysts remain optimistic heading into year-end, pointing to 13% earnings growth expectations and seasonal tailwinds as key supports.
Stock Moves Deciphered 📈
⚡️ Enphase Energy (ENPH)
The solar technology company surged 8.70% as its IQ8 Microinverters were selected for new solar projects and battery systems qualified for San Diego savings programs.
A CEO insider purchase, combined with the broader market rally in renewable energy stocks, added momentum to the clean energy stock.
💾 Western Digital (WDC)
The data storage company jumped 6.90% after Loop Capital raised its price target to $250, citing robust demand for hard drives from AI data centers.
Recent quarterly earnings that beat expectations, along with optimism across the AI infrastructure space, drove the rally.
🏥 Centene (CNC)
The managed care company plummeted 8.80% after a proposal was made to redirect Affordable Care Act subsidies directly to consumers, bypassing insurers.
The move threatens Centene's heavily government-dependent business model, sparking concerns about future revenue streams.
Headlines You Can't Miss 👀
📦 TreeHouse Foods to be acquired by Investindustrial for $22.50 per share in cash—an 18% premium valuing the food processor at nearly $3 billion.
🛫 China halted several rare earth mineral export restrictions to the U.S. for one year as trade tensions eased between the two nations.
💰 Warren Buffett to accelerate giving away his $149 billion estate to his children's foundations while maintaining significant Berkshire shares during the CEO transition.
⚖️ Supreme Court oral arguments on Trump's sweeping tariffs could reshape risk assets, particularly benefiting international equities and EM plays, according to JPMorgan.
📊 Fed Governor Stephen Miran pushed for a half-point rate cut in December, citing economic uncertainty from tariffs as a reason for accommodation.
🌏 Goldman Sachs upgraded Indian equities to overweight, seeing improved growth prospects after significant underperformance and foreign de-risking.
✈️ President Trump threatened to dock air traffic controllers' pay if absent from work, offering $10,000 bonuses to those who didn't take time off during the shutdown.
💳 Affordable Care Act subsidy proposal to redirect payments directly to consumers threatens government-sponsored insurer business models, triggering healthcare stock sell-offs.
Trending Stocks 📊
🚗 CarMax (KMX)
Morgan Stanley downgraded the used car retailer to equal weight from overweight, slashing its price target by $21 to $35.
The move followed weak preliminary guidance and the unexpected resignation of CEO Bill Nash. Shares have tumbled nearly 60% in 2025.
⛏️ MP Materials (MP)
Deutsche Bank upgraded the rare earth mine operator to buy, raising its price target to $71.
The Pentagon has become the company's largest shareholder, and the stock has soared 276% year-to-date, driven by support from the Trump administration for domestic critical minerals.
🛒 Instacart (CART)
The grocery delivery platform rose over 1.5% after topping Q3 earnings with revenues climbing 10% to $937 million.
New CEO Chris Rogers issued upbeat guidance, highlighting AI-powered tools and deepening retailer partnerships as growth drivers.
What’s Next?
Key market and macro news 👇
🤖 AMD hosts financial analyst day Tuesday—first in three years—with expectations for AI partnership updates.
⛽️ Following its earnings release on November 10, Occidental Petroleum will hold a conference call.
💰 Oklo and Nebius Group are also scheduled to report their earnings, which will be watched by investors in the energy and cloud computing sectors, respectively.
📊 The National Federation of Independent Business (NFIB) will release its Small Business Optimism Index for October.
🧑💻 The United Kingdom will release several key labor market indicators, including the Average Earnings Index, Claimant Count Change, and the unemployment rate.
Chart of the Day
Meme of the Day
Great investing starts with great information.
Forward The Market Scoop to anyone who wants to stay ahead of the market through a pertinent and entertaining newsletter format.
DISCLAIMER: None of this is financial advice. The newsletter is strictly educational and is not investment advice or a solicitation to buy or sell assets or make financial decisions. Please exercise caution and conduct your own research.